Tonix Pharmaceuticals stock halted ahead of FDA approval news
Director Charles J. Homcy of BridgeBio Pharma, Inc. (NASDAQ:BBIO) sold a total of $13.9 million in common stock, according to a Form 4 filing with the Securities and Exchange Commission. The sale comes as BridgeBio trades near its 52-week high of $49.77, having delivered an impressive 104% return over the past year. According to InvestingPro analysis, the stock currently appears overvalued relative to its Fair Value.
The sales, which occurred on August 8 and August 11, 2025, involved three separate transactions. On August 8, Homcy sold 191,662 shares at a weighted average price ranging from $45.395 to $46.38, and another 58,338 shares at a weighted average price between $46.40 and $46.84. On August 11, Homcy sold 50,000 shares at $48. The transactions were executed under a pre-arranged Rule 10b5-1 sales plan adopted on May 8, 2025. Following the transactions, Homcy directly owns 916,674 shares of BridgeBio Pharma, which now commands a market capitalization of $9.36 billion. Analyst price targets for the stock range from $41 to $95, reflecting mixed sentiment about the company’s valuation. Get deeper insights into BridgeBio’s financial health and growth prospects with a comprehensive Pro Research Report, available exclusively on InvestingPro.
In other recent news, BridgeBio Pharma reported a notable surge in revenue for the second quarter of 2025, reaching $110.6 million. This figure exceeded forecasts by 10.87%, which had anticipated $99.72 million. However, the company’s earnings per share (EPS) fell short, reporting a loss of $0.95 against an expected loss of $0.75. Meanwhile, Attruby sales reached $71.5 million, surpassing Oppenheimer’s estimate of $71 million and consensus expectations of $65 million, although they did not meet broader market expectations. Oppenheimer subsequently raised its price target for BridgeBio Pharma to $61.00, maintaining an Outperform rating. TD Cowen also reiterated its Buy rating, highlighting the strong performance of Attruby sales, which doubled in the second full quarter of availability. Both firms expressed confidence in the company’s recent performance, with TD Cowen setting a price target of $60.00. These developments reflect growing interest and positive sentiment from analysts regarding BridgeBio Pharma’s financial trajectory.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.